
Rezolute (RZLT) Stock Forecast & Price Target
Rezolute (RZLT) Analyst Ratings
Bulls say
Rezolute is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for rare and metabolic diseases. With a strong pipeline and a focus on improving patient outcomes and reducing treatment burdens, the company is well-positioned for success in the biopharmaceutical industry. Revenue and value creation depend on the successful development and regulatory approvals of its drug candidates, which have shown strong efficacy signals and potential peak sales in the hundreds of millions. A positive readout from the upcoming pivotal study for its lead candidate, ersodetug, could lead to a significant increase in stock price, making Rezolute an attractive investment opportunity.
Bears say
Rezolute is currently in the clinical stage of its pipeline, with potential revenues and value creation hinging on successful product development and regulatory approvals. Interim Phase 3 results for ersodetug in tumor hyperinsulinism have given the company a positive outlook, with potential distinct approval pathway from CHI. However, with a price target of $11/share and sensitivity tables showing a $400k-600k annual list price for cHI, financials suggest that the current price may not accurately reflect the company's underlying value.
This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.
Rezolute (RZLT) Analyst Forecast & Price Prediction
Start investing in Rezolute (RZLT)
Order type
Buy in
Order amount
Est. shares
0 shares